Efficacy of first-line treatment with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) alone or in combination with chemotherapy for advanced non-small cell lung cancer (NSCLC) with low-abundance mutation-Reference-Cited by-同舟云学术

Efficacy of first-line treatment with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) alone or in combination with chemotherapy for advanced non-small cell lung cancer (NSCLC) with low-abundance mutation

Published:2019-02 Issue: Volume:128 Page:6-12
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Yan Xiangtao,Wang Huijuan,Li Peng,Zhang Guowei,Zhang Mina,Yang Jinpo,Zhang Xiaojuan,Zheng Xuanxuan,Ma Zhiyong

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference20 articles.

1. Phase II and III trials: comparison of four chemotherapy regimens in advanced non small-cell lung cancer (ECOG 1594);Fisher;Clin. Lung Cancer,2000

2. Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma;Mok;N. Engl. J. Med.,2009

3. Efficacy according to blind independent central review: post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC;Wu;Lung Cancer,2017

4. Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802);Zhou;Ann. Oncol.,2015

5. Relative abundance of EGFR mutations predicts benefit from gefitinib treatment for advanced non-small-cell lung cancer;Zhou;J. Clin. Oncol.,2011

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. SAFE-MIL: a statistically interpretable framework for screening potential targeted therapy patients based on risk estimation;Frontiers in Genetics;2024-08-15

2. Tyrosine kinase inhibitor–induced hypothyroidism: mechanism and clinical implications;European Journal of Clinical Pharmacology;2024-03-14

3. Concordance of Abundance for Mutational EGFR and Co-Mutational TP53 with Efficacy of EGFR-TKI Treatment in Metastatic Patients with Non-Small-Cell Lung Cancer;Current Oncology;2023-09-15

4. Effects of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) targeted combined chemotherapy on immune function, tumor markers and oxidative stress in patients with stage IV lung adenocarcinoma;Pakistan Journal of Medical Sciences;2023-03-27

5. Concurrent classic driver oncogenes mutation with ROS1 rearrangement predicts superior clinical outcome in NSCLC patients;Genes & Genomics;2022-11-29